Previous close | 0.1794 |
Open | 0.1887 |
Bid | 0.1800 x 1000 |
Ask | 0.1880 x 3200 |
Day's range | 0.1700 - 0.1940 |
52-week range | 0.1300 - 1.6700 |
Volume | |
Avg. volume | 786,014 |
Market cap | 14.684M |
Beta (5Y monthly) | 0.38 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.
The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up.
Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.